Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model

Schuetz, C. Andy; Herick, Andrew van; Alperin, Peter; Peskin, Barbara; Hsia, Judith; Gandhi, Sanjay

doi:10.3111/13696998.2012.704459

Cited by 16 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, Archimedes covers indications such as coronary artery disease, diabetes and its complications, congestive heart failure, stroke and hypertension (Schuetz et al ., ). It can, for example, be used to compare treatments, guidelines or disease management programmes, taking into account comorbidities to predict long‐term outcomes or outcomes in different populations (Schlessinger and Eddy, ; Schuetz et al ., ). Long‐term health outcomes can be calculated from short‐term biological outcomes or to different populations (e.g.…”

Section: Resultsmentioning

confidence: 97%

GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world

Panayidou

Gsteiger

Egger

et al. 2016

Research Synthesis Methods

View full text Add to dashboard Cite

The performance of a drug in a clinical trial setting often does not reflect its effect in daily clinical practice. In this third of three reviews, we examine the applications that have been used in the literature to predict real‐world effectiveness from randomized controlled trial efficacy data. We searched MEDLINE, EMBASE from inception to March 2014, the Cochrane Methodology Register, and websites of key journals and organisations and reference lists. We extracted data on the type of model and predictions, data sources, validation and sensitivity analyses, disease area and software. We identified 12 articles in which four approaches were used: multi‐state models, discrete event simulation models, physiology‐based models and survival and generalized linear models. Studies predicted outcomes over longer time periods in different patient populations, including patients with lower levels of adherence or persistence to treatment or examined doses not tested in trials. Eight studies included individual patient data. Seven examined cardiovascular and metabolic diseases and three neurological conditions. Most studies included sensitivity analyses, but external validation was performed in only three studies. We conclude that mathematical modelling to predict real‐world effectiveness of drug interventions is not widely used at present and not well validated. © 2016 The Authors Research Synthesis Methods Published by John Wiley & Sons Ltd.

show abstract

Section: Resultsmentioning

confidence: 97%

GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world

Panayidou

Gsteiger

Egger

et al. 2016

Research Synthesis Methods

View full text Add to dashboard Cite

show abstract

“…Cannon et al [20] started with pravastatin 40 mg/day or atorvastatin 80 mg/day after 10 days of admission. While Schwartz et al [1] show that high dose of atorvastatin 80 mg/day within 24-96 hours after ACS occurrence reduced cardiovascular events during the few first weeks from initial therapy.…”

Section: Discussionmentioning

confidence: 96%

“…[20] начинали лечение правастатином 40 мг/сут или аторвастатином 80 мг/сут через 10 дней после поступления, в то время как Schwartz и соавт. [1] продемонстрировали, что назначение высокой дозы аторвастатина 80 мг/сут в течение 24-96 ч после развития ОКС снижает риск сердечно-сосудистых событий в первые несколько недель от начала терапии.…”

Section: Discussionunclassified

“…We included 130 patients of both genders aged from 18 to 70 years old who fulfilled WHO criteria for the diagnosis of ACS (ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [non-STEMI], unstable angina [UA]). Only 100 patients fulfilled the criteria and were randomized from first Острый коронарный синдром (ОКС) рассматривается как подгруппа сердечно-сосудистых заболеваний (ССЗ) и является ведущей причиной заболеваемости и смертности в мире [1]. Было установлено, что от ССЗ ежегодно умирает более 17 млн человек, от ОКС -от 3 до 8 на 1000 больных, что также ассоциируется с высокой частотой длительных госпитализаций [2][3][4].…”

Section: Methodsunclassified

“…Acute coronary syndrome (ACS) considered as a subgroup of cardiovascular diseases (CVD), which is the most leading cause of mortality and morbidity worldwide [1]. It was estimated that more than 17 million subjects are dying from CVD each year and 3 to 8 per 1000 persons suffering from ACS that associated with high rate of long hospitalization [2][3][4].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome

Mostafa

Elrabat

Mahrous

et al. 2018

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Background. Dyslipidemia is one of the most serious modifiable risk factors for acute coronary syndrome which is the most leading cause of mortality and morbidity worldwide. Aim. To assess the short-term safety and efficacy of full dose rosuvastatin and atorvastatin in patients with acute coronary syndrome. Material and methods. Single center, prospective, randomized study included 100 patients who were randomized from first 24-hour of admission to either atorvastatin 80 mg daily (group 1) or rosuvastatin 40 mg daily (group 2). Primary outcomes included levels of inflammatory markers (erythrocyte sedimentation rate [ESR], high-sensitive C-reactive protein [hs-CRP] and total leukocyte count [TLC]) after 4 weeks of treatment and lipid profile after 3 months. Secondary outcomes included recurrent myocardial infarction, recurrent angina, stroke and side effects. Results. At admission, both groups were comparable in age, without statistically significant difference regarding risk factors (diabetes, hypertension, smoking and obesity), echocardiography (end-diastolic volume, end-systolic volume and ejection fraction), laboratory parameters of inflammation and lipid profile. After 1 month, there was insignificant difference between rosuvastatin and atorvastatin in the reduction of ESR, Hs-CRP or TLC. After 3 months rosuvastatin showed statistically significant reduction in the level of low-density lipoprotein cholesterol, triglyceride (p<0.001) and significant increase in high-density lipoprotein cholesterol (p<0.001) when compared to atorvastatin and at the same time the rosuvastatin group was safer regarding liver enzymes elevation, p<0.001 for alanine and p<0.01 for aspartate aminotransferases, respectively. Conclusions. Our findings demonstrated that rosuvastatin 40 mg/day is safer and more effective than the atorvastatin 80 mg/day in the terms of lipid parameters and inflammatory biomarkers.

show abstract

Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over

et al. 2019

View full text Add to dashboard Cite

Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model

Cited by 16 publications

References 25 publications

GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world

GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world

Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome

Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over

Contact Info

Product

Resources

About